Inventor · disambiguated record
Kristen Mae Hege
Also filed as: HEGE KRISTEN · HEGE KRISTEN M · HEGE KRISTEN MAE
14 granted patents·22 pending applications·73 citations·filing 2012–2024
90Inventor score
Top patents by PatentIndex Score
36 records- 0192US9493466B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2012·Granted Nov 15, 2016·7 cites·5 claims
- 0290US9474757B2Methods for treating cancer using TOR kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Granted Oct 25, 2016·16 cites·20 claims
- 0390US9119854B2Methods for treating cancer using combination therapyCELGENE CORP·Filed 2014·Granted Sep 1, 2015·8 cites·22 claims
- 0489US9505764B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Nov 29, 2016·11 cites·33 claims
- 0589US9358232B2Methods for treating cancer using TOR kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Granted Jun 7, 2016·13 cites·6 claims
- 0688US9375443B2Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinibSIGNAL PHARM LLC·Filed 2013·Granted Jun 28, 2016·12 cites·4 claims
- 0782US9937170B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2016·Granted Apr 10, 2018·1 cites·5 claims
- 0881US9630966B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Apr 25, 2017·4 cites·6 claims
- 0978US11096940B2Treatment of hepatocellular carcinoma characterized by hepatitis B virus infectionCELGENE CORP·Filed 2018·Granted Aug 24, 2021·1 cites·42 claims
- 1076US2025123281A1Uses of anti-bcma chimeric antigen receptorsCELGENE CORP·Filed 2024·Application pending·0 cites
- 1174US2022273650A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2021·Application pending·0 cites
- 1271US11166950B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Nov 9, 2021·0 cites·5 claims
- 1371US2023338370A1Treatment of Cancer with TOR Kinase InhibitorsSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 1466US2020113896A1Methods for treating cancer using tor kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2019·Application pending·0 cites
- 1560US2021371522A1Cd47 antibodies and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 1660US2021128619A1Uses of anti-bcma chimeric antigen receptorsCELGENE CORP·Filed 2020·Application pending·0 cites
- 1758US9937169B2Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapySIGNAL PHARM LLC·Filed 2014·Granted Apr 10, 2018·0 cites·4 claims
- 1858US2022175770A1Treatment of hepatocellular carcinoma characterized by hepatitis b virus infectionCELGENE CORP·Filed 2021·Application pending·0 cites
- 1956US10391092B2Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapySIGNAL PHARM LLC·Filed 2018·Granted Aug 27, 2019·0 cites·9 claims
- 2053US10183019B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2017·Granted Jan 22, 2019·0 cites·5 claims
- 2153US2014314673A1Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Application pending·0 cites
- 2253US2014314752A1Methods for treating cancer using tor kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Application pending·0 cites
- 2352US9980963B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2016·Granted May 29, 2018·0 cites·11 claims
- 2450US2013245027A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 2549US2023057602A1Methods of treatment with antibodies against bcma and cd3BRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2648US2021330788A1Uses of anti-bcma chimeric antigen receptorsCELGENE CORP·Filed 2019·Application pending·0 cites
- 2747US2020255515A1Cd47 antibodies and methods of use thereofCELGENE CORP·Filed 2017·Application pending·0 cites
- 2845US2023190798A1Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereofJUNO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2945US2023087953A1Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereofJUNO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3044US2016008356A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2014·Application pending·0 cites
- 3143US2015099754A1Treatment of cancer characterized by gene mutationsSIGNAL PHARM LLC·Filed 2014·Application pending·0 cites
- 3243US2014113904A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3342US2013245029A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3442US2013245026A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3542US2013245028A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 3638US2018369241A1Treatment of cancer with dnapk inhibitorsCELGENE CORP·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →